Bio-Rad Laboratories (NYSE:BIO) and Valeritas (OTCMKTS:VLRXQ) Financial Contrast

Bio-Rad Laboratories (NYSE:BIO) and Valeritas (OTCMKTS:VLRXQ) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bio-Rad Laboratories and Valeritas, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	1	3	2	0	2.17
Valeritas	0	0	0	0	0.00

Bio-Rad Laboratories presently has a consensus price target of $339.75, suggesting a potential upside of 11.29%. Given Bio-Rad Laboratories’ stronger consensus rating and higher possible upside, equities analysts plainly believe Bio-Rad Laboratories is more favorable than Valeritas.

Valuation & Earnings

This table compares Bio-Rad Laboratories and Valeritas”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58 billion	3.19	$759.90 million	$27.91	10.94
Valeritas	N/A	N/A	N/A	N/A	N/A

Bio-Rad Laboratories has higher revenue and earnings than Valeritas.

Profitability

This table compares Bio-Rad Laboratories and Valeritas’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	29.42%	3.86%	2.70%
Valeritas	N/A	N/A	N/A

Institutional and Insider Ownership

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.0% of Valeritas shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Bio-Rad Laboratories beats Valeritas on 9 of the 9 factors compared between the two stocks.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

About Valeritas

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.